Clinical Trials Logo

Malignancies clinical trials

View clinical trials related to Malignancies.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05253105 Withdrawn - Malignancies Clinical Trials

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Start date: March 15, 2022
Phase: Phase 1
Study type: Interventional

The primary objective is to assess the safety and tolerability of TAB006 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB006 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB006, 2) evaluate antitumor activity of TAB006 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB006 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB006.